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Background: Regional and ethnic differences in the presentation and prognosis of
sarcoidosis have been reported.
Objectives: To describe and compare the clinical characteristics of sarcoidosis among
Arabs and South East Asians (SEA).
Methods: Data on patients with sarcoidosis were collected retrospectively 1983–1995 and
prospectively 1995–2003.
Results: A total of 142 patients, 57% females and 80% Arabs, were identified. The age at
onset shows the majority of cases (45%) among Arab males occur at 30–39 years, 60% of
Arab females occur at 40–59 years and 61% of SEA males occur at 40–49 years. The most
common symptoms were cough 77.5%, dyspnoea 54.2%, fever 31.0%, arthralgia 19%, uveitis
14.8%, erythema nodosum 14.8%, and lymphadenopathy 12%. The radiological stage at
presentation was stage 0,2.1%, I,44.4%, II,42.3%, and III,11.3%. The frequency of either
stage 0 or I was higher among SEA (62%) compared to Arabs 42.5%, p ¼ 0.05.
Conclusion: There is a peak of sarcoidosis among Arab males at 30–39 years, Arab females
at 40–59 years and SEA males at 40–49 years. Arab patients presented more frequently
with either stage II or III compared to SEA who usually present with stage 0 or I.
& 2007 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
e phosphatase; ALT, serum
aspartate aminotransferase;
computerised tomography;
monoxide; ERS, European
iratory volume in 1 s; FVC,
function tests; SACE, serum
total lung capacity; WASOG,
her granulomatous disorders.
38907.
u.kw (N. Behbehani).Introduction
Sarcoidosis is seen all over the world and affects both sexes,
all races and all ages.1 But significant heterogeneity in
clinical characteristics and severity of the disease among
patients from different ethnic and racial groups have been
described.2 Sarcoidosis in blacks appears to be more severe
while whites are likely to present with mild disease.3 There
are only a few reports that have been published from Arab
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Khan and colleagues reported that in native Saudis the
disease was characterized by severe constitutional symp-
toms, relatively frequent eye involvement and stage II
disease at presentation.5 We studied a much larger than
previously reported number of Arab and Asian patients
presenting with sarcoidosis in Kuwait. The purpose of this
study was to present the clinical characteristics of these
patients and compare the differences between these two
races with emphasis on age of onset, radiological stage of
the disease and the pattern of clinical involvement.Material and methods
Patients with sarcoidosis attending the respiratory out-
patient clinics of two major hospitals in Kuwait, Mubarak Al
Kabeer Hospital and Chest Diseases Hospital over a 20-year
period formed the study population. Data were collected
retrospectively for the period 1983–1995 and prospectively
for the period 1995–2003. The diagnosis of sarcoidosis was
accepted based on the following criteria. (1) Compatible
clinical presentation with histological finding of granuloma
from any of these organs: lymph nodes, lung, liver or skin
with negative smears and culture for tuberculosis and
without evidence of other granuloma-inducing agent. (2)
The clinical diagnosis was based on the finding of bilateral
symmetrical hilar lymph node enlargement without par-
enchymal lung involvement with or without erythema
nodosum, negative tuberculin skin test (o5mm tuberculin
test) and absence of features suggestive of other diagnosis
e.g. tuberculosis or lymphoma during a six-month observa-
tion period.7
The data on the symptoms, investigation results, chest
radiographic and CT scan findings, the pulmonary function
values and the treatment were collected and recorded in a
pre-defined data sheet. The common symptoms of cough,
dyspnoea, and fever and chest pain were recorded as per
the patient’s description. Weight loss was considered if
there was a documented decrease in weight of at least 5% in
the preceding few weeks or months. Arthralgia was defined
for this study as persistent pain in any joint for more than
two weeks with or without joint swelling or tenderness.
From 1995, all patients had ophthalmologic examination by
an ophthalmologist regardless of symptoms. When available
the initial chest radiographs were reviewed by the authors
for staging. Modified Scadding8 criteria was used for staging:
stage 0, no lung involvement; stage I, hilar enlargement
alone, stage II, hilar enlargement plus interstitial lung
disease, stage III, interstitial lung disease alone; and stage
IV, lung fibrosis. When the initial chest radiograph was not
available the information in medical records on staging was
used. Basic blood tests done included hemoglobin, erythro-
cyte sedimentation rate, liver enzymes and serum calcium.
Pulmonary function tests were done at presentation and
both the hospitals used the Master Lab with a body
Plethysmograph, Jaeger, Germany. The measurements in-
cluded forced expiratory volume in the first second (FEV1),
forced vital capacity (FVC), and the ratio of FEV1 to FVC,
total lung capacity (TLC), residual volume (RV), functional
residual capacity (FRC) and carbon monoxide diffusion
capacity estimation (DLCO), which were done in almost allpatients. The patients and patients’ records were evaluated
by two of the authors (NB, BJ) to determine radiological
stage and extra pulmonary organ involvement. The criteria
used to determine extra-pulmonary organ involvement were
similar to another published study.9 The treatment with
observation alone or oral corticosteroids was based on the
treating physician opinion. The long-term outcome was
determined for 103 patients. The outcome was divided into
good outcome (no residual disease), intermediate outcome
(mild to moderate residual disease) and poor outcome
(severe residual disease) according to previously published
criteria.10
The data were analyzed using the statistical package for
social sciences program (SPSS, PC Version 11.0). The various
variables were cross tabulated and the chi square test or
Fischer’s exact test was used to examine the differences
between Arabs and S.E. Asians in the categorical variables.
We decided to compare these two groups because these are
the largest racial groups in Kuwait. Approval to conduct the
study was taken from the local hospital authorities.Results
One hundred and forty two patients were diagnosed to have
sarcoidosis during the study period. Sixty (42.3%) were males
and 82 (57.7%) were females. Majority, 113 (79.6%), were
Arabs and the rest were S.E. Asians. One hundred and
nineteen (83.9%) patients had a histological confirmation of
their disease while in the rest the diagnosis was based on
clinico-radiological features. The histological diagnosis was
made from specimens obtained during bronchoscopy in 54
(38.0%), mediastinoscopy in 28 (19.7%) and thoracoscopic or
open lung biopsy in 15 (10.6%) patients. Peripheral lymph
nodes (5.6%), liver (5.6%) and skin (4.2%) were the other
major sites sampled for a tissue diagnosis. All patients with
clinico-radiological diagnosis had negative tuberculin test
and did not have easy to biopsy organ involvement.
Females were older, their mean age being 43.10711.81
years, when compared to males 37.69710.34 years,
p ¼ 0.006. There were 54 patients X40 years among
females compared to 26 (44.8%) among males, p ¼ 0.01.
Cough (77.5%), dyspnoea (54.2%) and fever (31.0%) were the
most common presenting symptoms. Extra-pulmonary man-
ifestations were observed as follows: uveitis in 21 (14.8%),
enlarged peripheral lymph nodes in 17 (12%), erythema
nodosum in 21 (14.8%), other skin abnormalities in 16
(11.3%), and hypercalcemia in 8 (5.6%) patients.
The comparison between Arabs and Asians is presented
in Table 1. There were 71 (62.8%) females in the Arab
population compared to 11 (37.9%) in Asians, p ¼ 0.002.
The mean age at presentation was slightly higher among
Asians (42.0076.60 years) than the Arabs (40.54712.47),
p ¼ 0.544. However, the age distribution shows that there is
a peak of sarcoidosis among Arab males at 30–39 years while
a broader peak occurs at the age 40–60 years among Arab
females, Fig. 1. The peak among Asian males occurs at the
age 40–49 years. The percentage of more advanced stages
(II, III and IV) was 57.5% among Arabs compared to 37.9%
among Asians, p ¼ 0.05. Subsequently, respiratory symp-
toms of cough and dyspn.ea were more common among
Arabs. Erythema nodosum was observed more frequently in
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Table 1 Clinical characteristics of the total population at presentation and the distribution among the Arabs and Asians with
the statistical significance.
Characteristics
Total Arabs Asians p
N ¼ 142 N ¼ 113 N ¼ 29
n% n% n%
Gender
Age
Females 82 57.7 71 62.8 11 37.9 0.02
Less than 40 years 59 42.4 50 45.5 9 31 0.2
Symptoms
Cough 110 77.5 88 77.9 22 75.9 0.807
Dyspnoea 77 54.2 69 61.1 8 27.6 0.002
Fever 44 31.0 31 27.4 13 44.8 0.077
Arthralgia 27 19.0 19 16.8 8 27.6 0.194
Weight loss 25 17.8 18 15.9 7 25.0 0.275
Chest pain 23 16.2 20 17.7 3 10.3 0.411
Signs
Uveitis 21 14.8 14 12.4 7 24.1 0.141
Erythema nodosum 21 14.8 17 15.0 4 13.8 1.000
Skin abnormalities other than E.N. 16 11.3 14 12.4 2 6.9 0.526
Lymph nodes 17 12.0 11 9.8 6 20.7 0.119
Hypercalcaemia 8 5.6 6 5.3 2 6.9 0.666
Stage
0 3 2.1 2 1.8 1 3.4
Stage I 63 44.4 46 40.7 17 58.6
Stage II 60 42.3 53 46.9 7 24.1 0.171
Stage III 14 9.8 10 8.8 4 13.8
Stage IV 2 1.4 2 1.8 0 0
Treatment
Steroids 111 78.2 87 79.1 24 85.7
No treatment 20 14.1 16 14.5 4 14.3
NSAID 4 2.8 4 3.6 0 0 0.753
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Fig. 1 The distribution of age at diagnosis divided into males and females among Arabs (A) and Asians (B). There is a peak among
Arab males at the age 30–39 years while a broader peak occurs at the age 40–60 years among Arab females, p ¼ 0.009. The peak
among Asian males occurs at the age 40–49 years.
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p ¼ 0.03, while it was observed more frequently in Asians
males 3 (16.7%) compared to Asian females 1 (9.1%),
p ¼ 1.00. Other skin manifestations were observed more
frequently among Arabs, 12.4%, compared to Asians, 6.9%,
p ¼ 0.5. The extra-pulmonary manifestations like uvietis,
peripheral lymphadenopathy and arthralgia were seen more
frequently among Asians compared to Arabs. Similarly,
constitutional symptoms of fever and weight loss were
also more common among the Asians (Table 1). Although
there were dissimilarities in the predominance of common
symptoms between Arabs and Asians, only shortness
of breath showed a statistically significant difference
(p ¼ 0.002) Table 1. AST and ALT were elevated in 11
(7.7%) patients but ALP was elevated in 69 (48.6%) patients
with no significant differences between Arabs and Asians.
Lung function tests results at presentation were available
for 128 (90%) patients. The mean7SD for FEV1, FVC, TLC
and DLCO as a predicted percentage were 73%721,
75%722, 84%718, and 83%725, respectively. There was
no difference in the mean values between Arabs and Asians
but there were more Arab patients (17.5%) with significantly
reduced FVC (o50%) compared to Asians (12%), p ¼ 0.5.
Majority of the patients received oral steroids while
observation was offered in around 14% of the patients.
There were no apparent differences in the treatment
received by both the groups (Table 1). Out of the initial
142 patients, 103 patients were followed up regularly for
more than 3 years. Among these 103 patients, 53(51%) had
complete resolution of their disease (good outcome), 33
(32%) had mild to moderate residual deficit (intermediate
outcome), while 17 (17%) had severe impairment in their
lung function or extra-pulmonary organ damage (poor
outcome). Two patients died during follow up period as a
result of sarcoidosis. There were no differences in the
outcome between the two groups, Arabs and Asians.Discussion
Sarcoidosis occurs in all regions of the world. Though the
clinical features generally follow a similar pattern, regional
differences in the presentation and prognosis have been
described. Sarcoidosis has been reported with a slight
clinical variation from the Middle East countries, but most
of the data are on a small number of patients.4–6,11 Our
study is by far the largest series from this part of the world.
Comparing the pattern of the disease among the two major
races, Arabs and Asians, we found that the respiratory
symptoms and the skin manifestations were more common
among the Arabs whereas constitutional and eye symptoms
were more frequent among Asians. Arab patients were
generally younger than the Asians and they presented with a
more advanced stage. Arab females presented at an older
age compared to the Arab males. Absence of documented
central nervous system, cardiac and parotid involvement at
presentation is noteworthy, but this may be partly due to
the fact that the patient population was recruited from the
respiratory clinics.
The higher proportion of females (62.8%) among Arabs is
consistent with earlier reports from this region4,5 and the
rest of the world.9,12 We cannot comment on the male tofemale ratio in Asians as 71% of Asian population in Kuwait
are male workers.13 The ATS/ERS/WASOG statement3
describes that ‘‘the disease consistently shows a predilec-
tion for adults under the age of 40, peaking in those aged
20–29 years’’. However, some of the studies reported from
Scandinavian countries, 14 Japan15 and the United States16
included a large percentage of older patients and the
women had a propensity to be older than men. Some suggest
that there is a bimodal age distribution of sarcoidosis with
a predominantly male peak occurring in the 20 s and a
predominately female peak occurring in the 50 s.17 Our
study shows that among Arab patients the male peak occurs
at 30–39 years and the female peak occurs at 40–60 years.
Despite the fact that 76% of Asian population in Kuwait is
below the age of 40 years,13 sarcoidosis peaks at age 40–49
among them, which is similar to other S.E. Asian countries.18
Non-specific constitutional symptoms such as fever and
weight loss may occur in about one-third of the patients.3 In
our study, weight loss of 5 kg or more was seen in 17.8% of
our patients and fever in 31%. Asian patients presented more
frequently with fever (44.8%) and weight loss (25%)
compared to Arab patients (27.4% and 15.9%). This finding
is consistent with the earlier observation that constitutional
symptoms occur more frequently in Indian patients com-
pared to white patients.18 Although at the time of diagnosis
most patients with sarcoidosis present with radiological
stages I–III, stage distribution has been somewhat variable in
different parts of the world. Patients from Japan were more
likely to have stage I disease compared to Europeans and
Americans.19 The majority of our patients presented with
either stage I (44.4% ) or stage II (42.3%). This is almost
similar to the recent ‘‘Case Control Etiologic Study of
Sarcoidois’’ (ACCESS) study9 which was done across the
United States with patients recruited from respiratory
clinics. However, in our study there were very few patients
with stage 0, only 2.1% compared to 8.3% in ACCESS. The
fact that Arabs had more advanced stage compared to Asians
is worth noting but difficult to explain. The radiological
stage distribution among our Asian population of stage I
(58.6%), stage II (24.1%) and stage III (13.8%) is different
from a study of 106 cases published from India; stage I 24%,
stage II 63% and stage III 13%.20 Our Asian population
belongs to three different countries of S.E Asia India,
Bangladesh and Srilanka and this may explain the differ-
ences observed. This difference in stage at presentation is
reflected in the fact that Arabs presented with more
respiratory symptoms and had lung biopsy more often for
diagnosis. Moreover, peripheral lymph nodes were involved
more commonly among the Asians, which made tissue
sampling easier.
Skin involvement in sarcoidosis is usually characterized by
erythema nodosum and other skin manifestation like Lupus
pernio, subcutaneous nodules and maculo/papular rash.21
Erythema nodosum was seen in 8.3% of patients in ACCESS
study while other skin manifestations occurred in around
15.9%. Erythema nodosum was observed in 14.8% of our
population with the majority of cases occurring among Arab
females. Though it was interesting to note that there were
more Asian males with erythema nodosum compared to the
females, the numbers were too small to make any
conclusions. Classically, skin involvement is known to occur
much less among Asians compared to Caucasians2 and we
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among Asians compared to Arabs.
The mean pulmonary function tests showed a slightly
reduced FEV1 and FVC but a normal TLC and diffusion. There
were no significant differences between the two races in the
mean values of the above parameters. Both restrictive and
obstructive pulmonary function abnormalities may be found
in sarcoidosis. Alterations in lung function tests are found
only in 20% of the patients with stage I disease and may
approach 70% as the stage advances.3 Hypercalcemia was
seen only in 5.6% of our patients. This is again another
interesting observation as hypercalcemia is a feature of
granulomatous disease and is usually seen more in those
areas with abundant sunshine and was reported in nearly a
quarter of smear-positive tuberculosis patients form this
region.22 Moreover, transient hypercalcemia is expected in
11% of sarcoid patients as reported in a worldwide review
article.23 Occult liver involvement is common in sarcoido-
sis.24 Nearly half of our patients had an elevation in ALP.
Although the decision on which patients with sarcoidosis
should receive systemic steroid is controversial,3,25 86% or
our patients received systemic steroids. This is not really
justified as 44% our patients had radiological stage I disease,
which is well known to have a high rate of spontaneous
remission. The decision to initiate treatment was based
purely on the individual treating physician’s choice and this
clearly calls for a need to revise this practice.
Sarcoidosis is not an uncommon disease in Kuwait and on
comparing the pattern of the disease among the two major
races, there were a few notable differences. Respiratory
symptoms and skin manifestations were more frequent
among the Arabs whereas constitutional symptoms were
more common among the Asians. There is a peak of
sarcoidosis among Arab males at the age 30–39 years while
the peak among Arab females occurs at the older age of
40–60 years.Conflict of interest
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